Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Adam G StewartPatrick N A HarrisMark D ChatfieldRoberta LittlefordDavid L PatersonPublished in: Trials (2021)
The MERINO-3 trial is registered under the US National Institute of Health ClinicalTrials.gov register, reference number: NCT04238390 . Registered on 23 January 2020.
Keyphrases
- gram negative
- open label
- study protocol
- phase iii
- clinical trial
- phase ii
- multidrug resistant
- klebsiella pneumoniae
- escherichia coli
- double blind
- randomized controlled trial
- phase ii study
- healthcare
- public health
- mental health
- quality improvement
- squamous cell carcinoma
- radiation therapy
- social media
- cross sectional
- smoking cessation